Oxurion announces the results of the Extraordinary General Meeting (EGM) held on
4 July 2024 and convenes a new EGM on 24 July 2024.
Leuven, BELGIUM - 4 July 2024 - 6:00 PM CET, Oxurion NV (https://oxurion.com/)
(Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, informs
its shareholders and the market that, at today's Extraordinary General Meeting,
the attendance quorum required to deliberate and vote on the items on the agenda
has not been reached, and that consequently, the Extraordinary General Meeting
was unable to deliberate or vote on the agenda items..
Attendance quorum not met
In accordance with the provisions of the Belgian Companies and Associations
Code, an attendance quorum of 50% of the outstanding shares was required to
deliberate validly on the agenda items. Despite requests for attendance
received, this quorum was not met. The meeting could therefore not proceed to
voting.
Convening of a new Extraordinary General Meeting
Consequently, Oxurion will convene an Extraordinary General Meeting on 5 July
2024 to be held on 24 July 2024 at 3pm in Brussels. The agenda remains unchanged
and concerns the proposal to consolidate the Company's outstanding shares at a
ratio of 1 for 10,000. This second Extraordinary General Meeting will deliberate
and decide validly, regardless of the proportion of the capital represented by
the shareholders present or represented.
The convening notice and other documents relating to the shareholders' meeting
are available on the Oxurion website, along with details of the agenda, location
and how shareholders can participate to the meeting.
Additional information
Shareholders are requested to regularly check Oxurion's press releases and
website for the latest information on the upcoming Extraordinary General
Meeting.
Oxurion would like to thank its shareholders for their understanding and
continued support.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation
standard of care ophthalmic therapies for the treatment of retinal disease.
Oxurion is headquartered in Leuven, Belgium. More information is available at
www.oxurion.com (https://oxurion.com/).
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events, or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report. This press release does not constitute an offer or
invitation for the sale or purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as amended,
or in compliance with an exemption therefrom, and in accordance with any
applicable U.S. state securities laws.
Contacts:
OXURION NV:
Pascal Ghoson, CEO
pascal.ghoson@oxurion.comÂ